Compare ASPI & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | FLGT |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.1M | 525.3M |
| IPO Year | 2022 | 2016 |
| Metric | ASPI | FLGT |
|---|---|---|
| Price | $4.92 | $14.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 4.0M | 402.1K |
| Earning Date | 04-10-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,849,000.00 | $18,730,000.00 |
| Revenue This Year | $68.41 | $10.09 |
| Revenue Next Year | $126.69 | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.92 | $13.46 |
| 52 Week High | $14.49 | $31.04 |
| Indicator | ASPI | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 37.20 |
| Support Level | $3.98 | $14.23 |
| Resistance Level | $5.90 | $16.76 |
| Average True Range (ATR) | 0.51 | 0.59 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 43.38 | 24.45 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.